+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective



Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective



Current Medicinal Chemistry 24(22): 2439-2458



Idiopathic pulmonary fibrosis (IPF) is the most common fibrosing lung disease and is caused by excessive lung scarring. IPF-associated severe mortality can be attributed to late diagnosis due to its generic symptoms, and more importantly due to the lack of effective therapies available. Despite extensive research in the past decades, lung transplant still remains the most effective treatment for IPF. Though two drugs recently approved by FDA, Pirfenidone and Nintedanib, have shown an ability to reduce the progression of disease. However, they have shown minimal survival benefits to patients. IPF is a multifaceted disorder with poorly understood pathophysiology. We believe that there are better therapeutic targets veiled in IPF pathophysiology, exploitation of which may improve current therapeutic approaches to the disease. We have performed an extensive literature search using several bibliographic databases for peer reviewed articles discussing molecular targets/pathways involved in the pathogenesis of the disease. Furthermore, studies involving exploitation of these therapeutic targets and potential therapeutic agents were identified. Recently, new and promising targets have been revealed from GWA studies and genetic microarrays of IPF patients. In this review, we discuss the efficacy and feasibility of several novel molecular targets including Semaphorin (SEMA) 7A, connective tissue growth factor, integrin αvβ6, caveolin-1, let 7-d, calcium activated potassium channel KCa3.1, matrix metalloproteinase-19, lysocardiolipin acetyltransferase, dimethylarginine dimethylaminohydrolase, and transglutaminase 2. These targets have all shown the potential to modulate IPF pathophysiology, thereby inhibiting disease progression. Information gained from this review will be valuable to this field, enabling the design and development of novel therapeutics for IPF.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 059718986

Download citation: RISBibTeXText

PMID: 28552057


Related references

Molecular targets for drug discovery in idiopathic pulmonary fibrosis: Work in progress. American Journal of Respiratory Cell and Molecular Biology 29(3 Part 2): S98-S101, 2003

Molecular targets in drugs discovery in idiopathic pulmonary fibrosis. Work in progress. American Journal of Respiratory Cell and Molecular Biology 29(3 Suppl): S98-101, 2003

Novel drug targets for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine 2016: 1-13, 2016

Molecular targets for new drug discovery to treat type 2 diabetes and obesity. Revista Medica de Chile 136(1): 107-117, 2008

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. International Journal of Molecular Sciences 20(3), 2019

Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-β1 pathway. European Journal of Medicinal Chemistry 157: 229-247, 2018

Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Current Medicinal Chemistry 16(11): 1400-1417, 2009

Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?. Vnitrni Lekarstvi 63(11): 796-801, 2018

Is it necessary to treat all patients with idiopathic pulmonary fibrosis?. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 18(3): 289-295, 2001

How i treat a patient with idiopathic pulmonary fibrosis. Revue Medicale de Liege 72(9): 381-383, 2018

Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine 131: 49-57, 2018

Molecular Approaches to Target Discovery: - Evaluating Targets for Antituberculosis Drug Discovery Programmes. Infectious Disorders - Drug Targets(Formerly Current Drug Targets - Infectious Disorders) 7(2): 120-126, 2007

Molecular approaches to target discovery:--evaluating targets for anti-tuberculosis drug discovery programmes. Infectious Disorders Drug Targets 7(2): 120-126, 2007

Ion channels as therapeutic targets: a drug discovery perspective. Journal of Medicinal Chemistry 56(3): 593-624, 2013

Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 53(5): 585-600, 2016